Yr Athro Aled Clayton

: Siarad Cymraeg
: Ar gael fel goruchwyliwr ôl-raddedig

Timau a rolau for Aled Clayton

Cyfarwyddwr Ymchwil
Yr Ysgol Meddygaeth

I am part of the Tissue Microenvironment Group, School of Medicine, Cardiff University which is a collection of diverse and international researchers with a multidisciplinary approach to science.

My own specialist insterst involves studies of cell-derived vesicles. This is now a rapidly growing and exciting area of biology, but we have been able to establish some expertiese in this field since the early 2000's. The group has published well over 90 papers, most in relation to vesicles, and their roles in subverting immune responses, in controlling the cancer microenvironment and as potential disease biomarkers.

I am interested in understanding the mechanisms by which vesicle biogenesis and secretion is controlled, and the impact such vesicles have on the development and progression of cancer; particularly focussing on prostate cancer. Developing tools and assays to quantify nano-vesicles in biological fluid specimens is also an important aspect of the group's activities.

Although my main focus is in cancer biology, I collaborate broadly with researchers in Cardiff including those in the schools of dentistry, engineering and optometry, and interact with other Universities, on aspects including cardiovascular disease, neurodegenerative diseases and other conditions that impact our society in significant ways.

2025

Durmaz, E., Esmaelli, M., Lewis, P., Cimaglia, G., Clayton, A. and Mead, B. 2025. R-28 cell-derived extracellular vesicles protect retinal ganglion cells in glaucoma. Neural Regeneration Research 10, article number: 4103. (10.4103/NRR.NRR-D-24-00709)

2013

Brennan, S. E., Nham, T., Clayton, A., McGowan, E. M., Cozzi, P. J. and Martiniello-Wilks, R. 2013. Prostate cancer exosomes offering novel circulating biomarkers for early cancer diagnosis and prognosis [Abstract]. The Journal of Gene Medicine 15(8-9), pp. 331-332. (10.1002/jgm.2740)
Midgley, A. C., Rogers, M. J., Hallett, M. B., Clayton, A., Bowen, T., Phillips, A. O. and Steadman, R. 2013. Transforming growth factor-β1 (TGF-β1)-stimulated fibroblast to myofibroblast differentiation Is mediated by hyaluronan (HA)-facilitated epidermal growth factor receptor (EGFR) and CD44 co-localization in lipid rafts. Journal of Biological Chemistry 288(21), pp. 14824-14838. (10.1074/jbc.M113.451336)
Webber, J. P. and Clayton, A. 2013. How pure are your vesicles?. Journal of Extracellular Vesicles 2, article number: 19861. (10.3402/jev.v2i0.19861)

2012

Kalra, H. et al. 2012. Vesiclepedia: A compendium for extracellular vesicles with continuous community annotation. PLoS Biology 10(12), article number: e1001450. (10.1371/journal.pbio.1001450)
Clayton, A. 2012. Cancer cells use exosomes as tools to manipulate immunity and the microenvironment. OncoImmunology 1(1), pp. 78-80. (10.4161/onci.1.1.17826)
Shah, K. M. et al. 2012. Induction of microRNA resistance and secretion in differentiating human endometrial stromal cells [Letter]. Journal of Molecular Cell Biology 5(1), pp. 67-70. (10.1093/jmcb/mjs058)
Beltrami, C., Clayton, A., Phillips, A. O., Fraser, D. J. and Bowen, T. 2012. Analysis of urinary microRNAs in chronic kidney disease. Biochemical Society Transactions 40(4), pp. 875-879. (10.1042/BST20120090)

2011

Clayton, A., Al-Taei, S., Webber, J. P., Mason, M. D. and Tabi, Z. 2011. Cancer exosomes express CD39 and CD73, which suppress T cells through adenosine production. The Journal of Immunology 187(2), pp. 676-683. (10.4049/jimmunol.1003884)

2010

Webber, J. P., Steadman, R., Mason, M. D., Tabi, Z. and Clayton, A. 2010. Cancer exosomes trigger fibroblast to myofibroblast differentiation. Cancer Research 70(23), pp. 9621-9630. (10.1158/0008-5472.CAN-10-1722)
Tabi, Z., Spary, L. K., Coleman, S. L., Clayton, A., Mason, M. D. and Staffurth, J. N. 2010. Resistance of CD45RA- T cells to apoptosis and functional impairment, and activation of tumor-antigen specific T cells during radiation therapy of prostate cancer. The Journal of Immunology 185(2), pp. 1330-1339. (10.4049/jimmunol.1000488)
Welton, J. L. et al. 2010. Proteomics analysis of bladder cancer exosomes. Molecular & Cellular Proteomics 9(6), pp. 1324-1338. (10.1074/mcp.M000063-MCP201)

2009

Mitchell, P. J., Welton, J. L., Staffurth, J. N., Court, J., Mason, M. D., Tabi, Z. and Clayton, A. 2009. Can urinary exosomes act as treatment response markers in prostate cancer?. Journal Of Translational Medicine 7(4), pp. n/a. (10.1186/1479-5876-7-4)
Navabi, H. et al. 2009. A clinical grade poly I:C-analogue (Ampligen®) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro. Vaccine 27(1), pp. 107-115. (10.1016/j.vaccine.2008.10.024)
Clayton, A. and Mason, M. D. 2009. Exosomes in tumour immunity. Current Oncology -Toronto- 16(3), pp. 46-49.

2008

Clayton, A., Mitchell, J. P., Court, J., Linnane, S., Mason, M. D. and Tabi, Z. 2008. Human tumor-derived exosomes down-modulate NKG2D expression. Journal of Immunology 180(11), pp. 7249-7258.
Mitchell, J. P., Court, J., Mason, M. D., Tabi, Z. and Clayton, A. 2008. Increased exosome production from tumour cell cultures using the Integra CELLine Culture System. Journal of Immunological Methods 335(1-2), pp. 98-105. (10.1016/j.jim.2008.03.001)

2007

Clayton, A., Mason, M. D., Mitchell, J. P. and Tabi, Z. 2007. Human tumour-derived exosomes selectively impair lymphocyte responses to Interleukin-2. Cancer Research 67, pp. 7458-7466. (10.1158/0008-5472.CAN-06-3456)

2006

Théry, C., Amigorena, S., Raposo, G. and Clayton, A. 2006. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Current Protocols in Cell Biology, article number: Unit 322. (10.1002/0471143030.cb0322s30)

2005

Clayton, A., Turkes, A., Mason, M. D. and Tabi, Z. 2005. Induction of heat shock proteins in B-cell exosomes. Journal of Cell Science 118(16), pp. 3631-3638. (10.1242/jcs.02494)
Coleman, S. L., Clayton, A., Mason, M. D., Jasani, B., Adams, M. and Tabi, Z. 2005. Recovery of CD8+ T-cell function during systemic chemotherapy in advanced ovarian cancer. Cancer Research 65(15), pp. 7000-7006. (10.1158/0008-5472.CAN-04-3792)
Coleman, S. L., Clayton, A., Mason, M. D., Jasani, B., Adams, M. and Tabi, Z. 2005. Recovery of CD8+ T-cell function during systemic chemotherapy in advanced ovarian cancer. Cancer Research 65(15), pp. 7000-6. (10.1158/0008-5472.CAN-04-3792)
Adams, M. et al. 2005. The rationale for combined chemo/immunotherapy using a Toll-like receptor 3 (TLR3) agonist and tumour-derived exosomes in advanced ovarian cancer. Vaccine 23(17-18), pp. 2374-2378. (10.1016/j.vaccine.2005.01.014)
Navabi, H. et al. 2005. Preparation of human ovarian cancer ascites-derived exosomes for a clinical trial. Blood Cells, Molecules, and Diseases 35(2), pp. 149-152. (10.1016/j.bcmd.2005.06.008)
Clayton, A. and Tabi, Z. 2005. Exosomes and the MICA-NKG2D system in cancer. Blood Cells, Molecules, and Diseases 34(3), pp. 206-213. (10.1016/j.bcmd.2005.03.003)

2004

Clayton, A., Turkes, A., Dewitt, S., Steadman, R., Mason, M. D. and Hallett, M. B. 2004. Adhesion and signaling by B cell-derived exosomes: the role of integrins. The FASEB Journal 18, pp. 977-979. (10.1096/fj.03-1094fje)

2003

Thomas, G. J., Clayton, A., Thomas, J., Davies, M. and Steadman, R. 2003. Structural and functional changes in heparan sulfate proteoglycan expression associated with the myofibroblastic phenotype. America Journal of Pathology 162(3), pp. 977-989.
Clayton, A., Harris, C. L., Morgan, B. P. and Mason, M. D. 2003. Antigen-presenting cell exosomes are protected from complement-mediated lysis by expression of CD55 and CD59. European Journal of Immunology 33(2), pp. 522-31. (10.1002/immu.200310028)
Blaber, R., Stylianou, E., Clayton, A. and Steadman, R. 2003. Selective regulation of ICAM-1 and RANTES gene expression after ICAM-1 ligation on human renal fibroblasts. Journal of the American Society of Nephrology 14(1), pp. 116-127. (10.1097/01.ASN.0000040595.35207.62)

2002

Savage, P. et al. 2002. Induction of viral and tumour specific CTL responses using antibody targeted HLA class I peptide complexes. British Journal of Cancer 86(8), pp. 1336-1342. (10.1038/sj.bjc.6600223)
Savage, P. et al. 2002. Anti-viral cytotoxic T cells inhibit the growth of cancer cells with antibody targeted hla class I/peptide complexes in scid mice. International Journal of Cancer 98(4), pp. 561-566. (10.1002/ijc.10219)

2001

Clayton, A., Thomas, J., Thomas, G. J., Davies, M. and Steadman, R. 2001. Cell surface heparan sulfate proteoglycans control the response of renal interstitial fibroblasts to fibroblast growth factor-2. Kidney International 59(6), pp. 2084-2094. (10.1046/j.1523-1755.2001.00723.x)
Clayton, A. et al. 2001. Analysis of antigen presenting cell derived exosomes, based on immuno-magnetic isolation and flow cytometry. Journal of Immunological Methods 247(1-2), pp. 163-174. (10.1016/S0022-1759(00)00321-5)

1999

Clayton, A. and Steadman, R. 1999. ICAM-1 interactions in the renal interstitium: a novel activator of fibroblasts during nephritis. Histology and Histopathology 14(3), pp. 861-870.
Clayton, A., Thomas, J., Thomas, G., Davies, M. and Steadman, R. 1999. Fibroblasts from the cortical interstitium express cell surface heparan sulphate proteoglycans [Abstract]. Kidney International 55(6), pp. 2588-2588. (10.1046/j.1523-1755.2002.t01-1-00456.x)
Evans, R. E., Clayton, A., Martin, J., Williams, J. D., Davies, M. and Steadman, R. 1999. Neutrophil binding stimulates the synthesis, release and activation of MMP 3 and MMP 2 from endothelial cells in vitro [Abstract]. Kidney International 55(5), pp. 2105-2105. (10.1046/j.1523-1755.1999.00404.x)

1998

Clayton, A., Evans, R. A., Pettit, E., Hallett, M., Williams, J. D. and Steadman, R. 1998. Cellular activation through the ligation of intercellular adhesion molecule-1. Journal of Cell Science 111(4), pp. 443-453.

1997

Evans, R. A., Clayton, A., Martin, J., Williams, J. D., Davies, M. and Steadman, R. 1997. Neutrophil binding stimulates the synthesis, release and activation of MMP 2 from endothelial cells in vitro. Journal of the American Society of Nephrology 8, pp. A2390-A2390.
Clayton, A., Williams, J. D. and Steadman, R. 1997. The ligation of ICAM-1 on renal cortical fibroblasts initiates the de novo expression of ICAM-1 and VCAM-1. Journal of the American Society of Nephrology 8, pp. A2385-A2385.
Clayton, A., Williams, J. D. and Steadman, R. 1997. Ligation of ICAM-1 on the surface of renal cortical fibroblasts stimulates de novo expression of ICAM-1 and VCAM-1 [Abstract]. Kidney International 52(1), pp. 262-263. (10.1038/ki.1997.329)
Clayton, A., Steadman, R. and Williams, J. D. 1997. Cells isolated from the human cortical interstitium resemble myofibroblasts and bind neutrophils in an ICAM-1--dependent manner. Journal of the American Society of Nephrology 8(4), pp. 604-615.

1996

Steadman, R., Clayton, A., Pettit, J., Hallett, B. and Williams, J. D. 1996. Leukocytes trigger an influx of calcium in renal interstitial fibroblasts through ligation ICAM-1. Journal of the American Society of Nephrology 7(9), pp. A2594-A2594.

1995

Clayton, A., Steadman, R. and Williams, J. D. 1995. Human renal cortical fibroblasts (RCF) bind leukocytes in-vitro through a CD18-dependent and VLA(4)-dependent interaction. Journal of the American Society of Nephrology 6(3), pp. 894-894.

We are interested in understanding how cells produce small fat-bubbles (vesicles), and why they seem to do this so extensively. Our studies focus on the role of such bubbles in changing the immediate surroundings of the cancer tissue. it seems these bubbles (exosomes) can interfere with the correct function of immune cells, they can encourage formation of blood vessels, and can hijack other neighbouring cells to behave abnormally- all of these effects assist the growth and ultimate spread of the tumour.

We can also detect exosomes in the urine and blood of cancer patients, and we are working hard on developing new methods to isolate exosomes from biological fluids, and to use these as means of discovering new indicators of disease. We have examined the complex array of protein molecules on the vesicles, and are beginning to also look at RNA-molecules, which hide inside the bubble.

Together, these studies will provide much needed information about how the cancer cells can dominate and take-over their microenvironments. Learning how to block these effects is likely to be very useful therapeutically. Pperhaps we can also use the presence of exosomes in urine/blood as future tests to support diagnoses and monitoring of cancer.

Funding sources

Cancer Research Wales, Programme grant:
Movember: The Movember Revolutionary Team Award
Prostate Cancer UK: British Heart Foundation:
British Lung Foundation:
CU & ReNeuron:
Tenovus Cancer Care:
Welsh Assembly Government NRN Sêr Cymru Award:

Fel llawer o academyddion sy'n canolbwyntio ar ymchwil, rwyf hefyd yn anghytuno â gweithgareddau addysgu israddedig ac ôl-raddedig Coleg y Gwyddorau Bywyd Biolegol , a'r Ysgol Meddygaeth.

Mae'r rhain yn cynnwys, ymhlith eraill:-

Graddau BSc a Ffarmacoleg rhyng-gyfrifedig, Ysgol Meddygaeth:

Cyfraniadau tuag at ddatblygu, cynnal a marcio prosiectau ymchwil yn y labordy.
Asesiad o gyflwyniadau ymchwil myfyrwyr a thraethodau hir.

Bioleg Moleciwlaidd Canser, Ysgol Meddygaeth:

Cyfarfod llawn, EV mewn bioleg canser, cyflwyniad sy'n cwmpasu pynciau gan gynnwys natur ac amrywiaeth EV, hanes darganfod EV, swyddogaethau EV mewn modiwleiddio imiwnedd, angiogenesis, actifadu stroma, lledaenu metastatig.

MBBCh, SSC Bl-1

Tutotials ac asesydd ar gyfer Prosiectau Adolygu llenyddiaeth dethol, a thiwtorialau/arddangosiadau achlysurol yn seiliedig ar ddulliau labordy ac ati.

Career overview

Snr Lecturer (08/2013-present), Division of Cancer & Genetics, Cardiff University
Lecturer; (08/2004 to 07/2013), School of Medicine, Cardiff University
Research Fellow (01/1999 to 07/2004) School of Medicine, Cardiff University
Research Fellow, (10/1996 to 12/1998) School of Medicine, Cardiff University

Education & qualifications

1997: PhD (Medicine), Institute of Nephrology, University of Wales College of Medicine.
1998: Diploma in Biomedical methods, University of Wales College of Medicine.
1993: BSc (Hons) Biochemistry, University of Wales College Cardiff

Anrhydeddau a dyfarniadau

Visiting Professor for the Finish Government inFlames Programme at the university of Turku https://inflames.utu.fi

Aelodaethau proffesiynol

Aelod Sylfaenol o'r Gymdeithas Ryngwladol ar gyfer fesiglau Allgellog (ISEV)
Aelod Sefydlu ac ymddiriedolwr Cymdeithas Llysiau Allgellog y Deyrnas Unedig https://www.ukev.org.uk

Pwyllgorau ac adolygu

Pwyllgorau Mewnol

Aelod o Uwch Dîm Arweinyddiaeth yr Ysgol Meddygaeth (SLT)
Cadeirydd, Darganfod i Arloesi Comittee (D2I), Ysgol Meddygaeth
Aelod a Chyd-gadeirydd, Pwyllgor Arloesi i Effaith (I2), Ysgol Meddygaeth
Pwyllgor Ymchwil y Brifysgol
Pwyllgor Cronfa Ymchwil WHRI

Pwyllgorau Allanol

2024-25: Pwyllgor Trefnu Rhyngwladol (IOC): Gweithdy ISEV ar Corona Biomoleciwlaidd, Brescia, Yr Eidal
2024-25: Gwobrau Arloesedd Prostate Cancer UK, panel grantiau.
2017: Pwyllgor Gwyddoniaeth ac Aelodaeth, Cymdeithas EV y Deyrnas Unedig
2017: Pwyllgor Cynllunio. Cyfarfod Trafod y Gymdeithas Frenhinol; EV's in the Tumour Microenvironment (adroddiadau cyhoeddedig)
2015-2017: Grŵp Astudiaethau Clinigol NCRI - Grŵp Cynghori Biomarcwyr Moleciwlaidd
2015 - Fforwm Fesigl Allgellog y Deyrnas Unedig, trefnydd cynadleddau blynyddol a chyd-drefnydd 2014, 2016 yn parhau.
2016 - Cymdeithas Ryngwladol ar gyfer fesiglau Allgellog, Pwyllgor Trefnu Lleol y Gynhadledd Flynyddol, Rotterdam
2016-2017- Pwyllgor Trefnu, Cyfarfod Trafod y Gymdeithas Frenhinol, EV yn y Microamgylchedd Canser, Llundain 2017.

PhD Arholwr

2024-25. PhD gan Gwrthwynebydd Cyhoeddi. Prifysgol Aalborg, Denmarc
2023. Gwrthwynebydd PhD, Prifysgol Helsinki.
2023. Arholwr Mewnol, PhD, Div. Canser a Geneteg, Caerdydd
2022. PhD Oponent, Prifysgol Aarhus, Denmarc
2021. Arholiad PhD Prifysgol Rhydychen.
2021. Arholwr Mewnol, Cardif PhD ar gyfer BIOSCI
2019. PhD Oponent, Prifysgol Gothenburg.
2018. Cadeirydd Arholi, Caerdydd PhD
2017. Arholwr Allanol, PhD St Andrews.
2017. Arholwr Mewnol, PhD, Caerdydd.
2016. Cadeirydd Arholi, Caerdydd MD.
2016. Arholwr Allanol, PhD Prifysgol Caerlŷr
2015. Ail wrthwynebydd, PhD Oslo, Norwy
2014. Arholwr Allanol, PhD Oxford Brookes
2013. Arholwr Mewnol, PhD, Caerdydd

Golygydd

2012-2017: Aelod o'r Bwrdd Golygyddol Cyswllt - Journal of Extracellular vesicles
2013-2016: Bwrdd Golygyddol, Journal of Circulating Biomarkers.

Mae gan y tîm ddiddordeb mawr mewn perswadio astudiaethau sy'n gysylltiedig â

Mesuriadau / dadansoddeg nano-fesigl
Cyfryngu vesicle-cyfryngu cyfryngu intercellular comunication gan gynnwys ceisiadau cyflenwi cyffuriau
feirysau mewn bioleg canser sylfaenol a all gynnwys swyddogaethau imiwnolegol, a rolau wrth fodiwleiddio ffibroblastau sy'n gysylltiedig â chanser
Cymhwyso fesiglau fel marcwyr canser (yn enwedig mewn canser y prostad).

Goruchwyliwr PhD:

Miss. Hanady Nehm, cyd-oruchwyliwr gyda Dr Ben Mead (OPTOM)

Gweithio ar therapiwteg fesigl ar gyfer y retina. SWBio, DTP

Miss. Jasmine Owen, cyd-oruchwyliwr gyda Dr Helen Pearson (ECSCRI, BIOSCI)

Ymchwilio i gelloedd strymegol mewn canser y prostad

Mr. Keran Hodson, cyd-oruchwyliwr gyda Dr. Toby Phesse (ECSCRI, BIOSCI)

Ymchwilio i gyfraniadau fesiglau i signalau Wnt-mewn canser.

Prosiectau'r gorffennol

Joanne Welton - Uwch Awdur Meddygol yn HEOR
Ridwana Chowdhury - Evox Therapeutics
Vincent Yeung - Sefydliad Ymchwil Llygaid Schepens | Ysgol Feddygol Harvard.
Alex Cocks - GSK
Sara Viega - Ysbyty Cyffredinol Massachusetts | Ysgol Feddygol Harvard.
Mariama Mbengue - Ysgrifennwr Meddygol

Contact Details

ClaytonA@caerdydd.ac.uk
+44 29225 10589
Adeilad Tenovus, Ystafell GF16, Ysbyty Athrofaol Cymru, Parc y Mynydd Bychan, Caerdydd, CF14 4XN
Neuadd Meirionnydd, Ystafell Llawr 1af, Deoniaeth, Ysbyty Athrofaol Cymru, Parc y Mynydd Bychan, Caerdydd, CF14 4YS

Themâu ymchwil

Arbenigeddau

Bioleg Celloedd
Bioleg celloedd canser
Canser y prostad
Llysiau allgellog
Biofarcwyr

Mae Medicentre Caerdydd wedi cynnal digwyddiad i hybu cydweithio rhwng y byd academaidd a byd diwydiant

24 June 2024

Gwyddonwyr Prifysgol Caerdydd yn derbyn £10k ychwanegol i sbarduno diagnosis o ganser y prostad

13 December 2021

External profiles

Google Scholar

Yr Athro Aled Clayton

Timau a rolau for Aled Clayton

Cyfarwyddwr Ymchwil

Trosolwyg

Cyhoeddiad

2025

2024

2023

2022

2021

2020

2019

2018

2017

2016

2015

2014